Saxenda Prescription Precautions And Storage

Saxenda is the product name, and the ingredient is liraglutide. Dieting is a difficult task for anyone, and for a while the supply was not smooth and a shortage was even reported. It is a drug of that much interest, but in the clinic many people come knowing only the name and the effect, without knowing the indications or precautions well. Saxenda is a prescription-only medication that requires a doctor's prescription, and it is not a drug recommended to everyone the same way. In this article, we organize, based on authoritative materials, by what principle it works, for whom it is considered, how to inject and store it, and what side effects you should know before starting.

Liraglutide, the ingredient of Saxenda, is similar in structure to a hormone called GLP-1 (glucagon-like peptide-1) secreted in our gut, and it is a drug that acts on its receptor. GLP-1 receptors are distributed in many sites such as the gastrointestinal tract, the central nervous system, and the pancreas, so their actions are also diverse.

Specifically, GLP-1 does the following.

• Slows the speed at which food goes down from the stomach, helping satiety last longer
• Acts on the central nervous system to suppress appetite. The part patients feel most in the clinic is precisely that the desire to eat itself decreases
• Is involved in blood sugar control, helping with weight management

However, Saxenda is not a magic drug but a drug that assists diet and exercise therapy. Both the U.S. Food and Drug Administration (FDA, 2014) and the domestic Ministry of Food and Drug Safety approval specify Saxenda as an adjunct therapy to a low-calorie diet and increased physical activity. It is better to start with a clear understanding from the beginning that it is not a treatment completed by the drug alone.

Saxenda is not a drug recommended to everyone simply for the reason of wanting to lose weight, but a drug decided by weighing indications and risk factors together. The FDA (2014) and the Ministry of Food and Drug Safety approval set a body mass index (BMI) criterion, defining as the target adults who fall into the obesity category, or who are overweight and have a weight-related comorbidity. Accurate application of the criteria requires evaluation through care.

Organizing the people who are often mentioned as candidates based on clinical experience in the original article, they are as follows.

• Patients with polycystic ovary syndrome, which often comes with insulin resistance
• People whose blood sugar management is not going well or who have been diagnosed with prediabetes
• People who need weight management and have experienced the side effects of existing appetite suppressants

Polycystic ovary syndrome is a representative case that mutually influences and is influenced by weight gain. How weight gain is connected to amenorrhea or menstrual irregularity is covered in more detail in a separate article, so looking at it together helps.

Saxenda is not used at the maintenance dose from the start; it is a drug titrated slowly to reduce gastrointestinal side effects. Based on the Ministry of Food and Drug Safety approval, it starts at 0.6 mg and is increased by 0.6 mg at weekly intervals, and the maintenance dose is usually 3.0 mg. It is administered by subcutaneous injection once a day.

However, it does not necessarily have to be raised mechanically every week. If appetite control is sufficient at the current dose and there are no adverse reactions, the method of maintaining at that dose can also be adjusted through care. As a principle, the titration speed and target dose are set to fit the individual's response.

We have organized in a table the points to remember about the injection method.

If you have questions before or after starting, rather than judging on your own, it is safer to confirm through an in-clinic visit or consultation.

Because Saxenda is a protein-class drug, the storage temperature directly affects the drug's stability. According to the Ministry of Food and Drug Safety approval, refrigerated (2–8 degrees) storage is recommended before opening. It must not be frozen, and direct sunlight and high temperature must be avoided.

The storage conditions of a pen that has started use differ a little. Generally, it is guided as being storable for up to a month at room temperature below 30 degrees or refrigerated. For the exact storage period and conditions, please follow the product instructions and the guidance of the medical institution that prescribed it. A drug stored incorrectly is difficult to guarantee in effect or safety, so it is good to pay attention to temperature management even when carrying it or traveling.

Saxenda is a drug whose administration is contraindicated for some patients or requires careful evaluation. Generalizing and conveying the content organized in the Ministry of Food and Drug Safety approval (precautions for use), it is as follows.

As cases where it must not be administered, people with hypersensitivity to the drug ingredient, and people with a personal or family history of medullary thyroid carcinoma (MTC) or who have multiple endocrine neoplasia type 2 (MEN2) are specified. This contraindication also matches the boxed warning of the FDA label (2014) and is based on the point that thyroid C-cell tumors were observed in animal experiments.

There are also not a few cases that should be administered with caution.

• People with severe heart failure, severe renal impairment, or hepatic impairment
• Those aged 75 or older
• People with inflammatory bowel disease or diabetic gastroparesis (concern about gastrointestinal adverse reactions)
• Type 2 diabetes patients using insulin or a sulfonylurea together (increased risk of hypoglycemia)

In particular, Saxenda must not be used as a substitute for insulin in diabetes patients receiving insulin. For these reasons, Saxenda always requires evaluation through care before starting, and honestly telling about underlying diseases and medications taken is the starting point of safety.

Every drug can have side effects, and Saxenda is no exception. The most common in the early stage are gastrointestinal symptoms. Because of the mechanism of slowing stomach movement and maintaining satiety, eating the same amount as usual can cause bloating, nausea, vomiting, indigestion, abdominal distension, and abdominal pain, and diarrhea or constipation may also accompany it. So in the early stage, a drug that aids stomach movement is sometimes prescribed together.

Other points to be aware of are as follows.

• Headache may appear
• An increase in heart rate is reported. According to the FDA label (2014), an increase of a few beats per minute on average was observed in clinical trials, and it was reversible upon discontinuation. If palpitations persist at rest, care is needed
• Rarely, acute pancreatitis, gallstones/cholecystitis, and dehydration are reported. If severe abdominal pain persists, you must stop administration and receive care

As pointed out in the original article, Saxenda is known to be relatively combinable even with alcohol consumption and to have a wide combination range with some antidepressants. However, the point that dieting while drinking alcohol is no different from not dieting remains unchanged. The pattern and degree of side effects may have individual variation, so if there are abnormal symptoms, please do not arbitrarily endure them but adjust through consultation.

Saxenda is a tool, not a destination. In large-scale clinical studies such as SCALE (2015), the drug was used as an adjunct therapy combined with a low-calorie diet and a certain amount or more of physical activity per week, and meaningful weight loss was reported in that combination. Conversely, it is known that a tendency for weight to increase again is observed when the drug is discontinued, so it is hard to maintain the effect if correction of eating habits and activity level is not accompanied.

In clinical experience, the reason results differ even with the same drug is, in the end, the difference in lifestyle habits and underlying condition. Cases are diverse—such as people who must first put their gut environment in order, or people who must use a drug that reduces adverse reactions together—so an individualized, tailored approach is needed. The article dealing with why, even in polycystic ovary syndrome management, the drug and lifestyle change should be looked at together is in the same vein. If weight and obesity treatment are new to you, we recommend first checking where weight gain or difficulty in appetite control originates.

If you are curious about whether Saxenda is suitable, dose adjustment, or side-effect management, please confirm a plan that fits your condition through a care consultation. Rather than asserting the effect, knowing accurately and starting safely leads to a better result.

Author: Lee Dong-hee Chief Director · Obstetrician-Gynecologist · View staff profile

First published January 28, 2024 · Last reviewed May 30, 2026

References: U.S. Food and Drug Administration FDA Saxenda Approval Information and Label (2014, 2020, 2025), Ministry of Food and Drug Safety Liraglutide Approval Precautions for Use, SCALE Clinical Trial NEJM (2015)

This article is intended to provide general health information and does not replace individual diagnosis or treatment. If you have symptoms, please consult through a medical examination.